Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Amgen (NQ: AMGN )

263.38 +2.19 (+0.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
48 49 Next >
The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock
Investors are closely watching two key spaces that could spark Lilly stock. 
Via Investor's Business Daily
If You Invested $100 In This Stock 20 Years Ago, You Would Have $500 Today
Via Benzinga
2 Market-Beating Stocks to Buy in 2023 and Hold Forever
For these companies' shareholders, it may be tempting to take profits right now. But both stocks can keep growing for a while. 
Via The Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
Vertex Therapeutics and Amgen have the building blocks for long-term success. 
Via The Motley Fool
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
Stifel raised argenx SE (NASDAQ: ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. argenx shares rose 1.1% to $387.07 in pre-market trading. 
Via Benzinga
Interest Rate Hikes Won't Stop These 2 Cash-Rich Growth Stocks
Even if interest rates go up, you likely won't need to worry about these stocks. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Market Rally Pressured On Fed Rate Outlook; Moderna, Boeing, Tesla In Focus: Weekly Review
Moderna spiked on a cancer vaccine while Tesla continued to dive. 
Via Investor's Business Daily
2 Best Biotech Stocks to Buy Right Now
Demand for medicines and vaccines has nowhere to go but up over the long run. 
Via The Motley Fool
20 Dividend Growth Stocks For Faster Growth And Profit
The equal weight growth model was willing to accept faster-growing companies with lower current dividend yields, but faster-growing dividends. 
Via Talk Markets
The Best ETF For Dividend Yield And Dividend Growth
This ETF checks off all the boxes in terms of performance, dividend growth, and solid yield. 
Via The Motley Fool
Finding 20 Dividend Growth Stocks In A Bad Market
Starting in 2012, it became more and more difficult for prudent dividend growth stock investors looking for income. The stock market was trading at excessive valuations, and interest rates were at... 
Via Talk Markets
Harpoon Therapeutics Remains Volatile After Promising News
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. 
Via MarketBeat
The Bullish Call Eli Lilly Made For Its Next-Gen Obesity Drug, A Rival To Novo, Amgen
All eyes are on tirzepatide, but its next-generation weight-loss shot could be even better. 
Via Investor's Business Daily
Pinterest To Rally Around 23%? Here Are 10 Other Price Target Changes For Tuesday
Via Benzinga
Cramers Says These 3 Big Deals Aided Monday's Market Rally: 'When Companies Start Buying Each Other At A Big Premium...'
Prominent market commentator Jim Cramer said three corporate deals announced on Monday aided the rally seen at the beginning of the week,  
Via Benzinga
Nasdaq, S&P 500 Futures Soar Amid Optimistic Expectations Concerning Nov. Inflation: Oracle, Tesla, Pinterest Among Early Movers
The index futures point to a modestly higher opening for the market on Tuesday, although the November consumer price inflation due ahead of the open could sway sentiment either way depending on how the... 
Via Benzinga
Tesla, Apple, Rivian, Horizon, Paypal: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed over 1% higher on Monday after last week’s subdued performance. 
Via Benzinga
Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues
FDA action on its KRAS-blocking drug could help recently downtrodden Mirati. 
Via Investor's Business Daily
Here's Where Amgen's Loan To Acquire Horizon Therapeutics For $28B Ranks Among M&A Deals In 2022
Amgen Inc's (NASDAQ: AMGN) deal to acquire Horizon Therapeutics (NASDAQ: HZNP) requires a sizable loan that ranks among the biggest debt commitments for 
Via Benzinga
Why Horizon Therapeutics Stock Is Soaring Today
Amgen's planned acquisition of Horizon could close in the first half of next year. 
Via The Motley Fool
What's Going On With Amgen Stock Today?
Amgen Inc (NASDAQ: AMGN) shares are trading lower Monday after the company announced it will acquire Horizon Therapeutics (NASDAQ: HZNP) 
Via Benzinga
Horizon Therapeutics (HZNP) Stock Pops on HUGE Amgen Deal
HZNP stock is up on news that Horizon Therapeutics is being bought by Amgen in a friendly deal that's positive for both companies. 
Via InvestorPlace
Amgen To Buy Rare Diseases Drugmaker Horizon Therapeutics In $28.3 Billion Deal
The deal comes a day after Sanofi dropped out of the bidding process. 
Via Investor's Business Daily
These 2 Nasdaq Stocks Are Soaring on Merger News
Find out which companies are attracting interest from prospective buyers. 
Via The Motley Fool
Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12
Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU 
Via Benzinga
Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share
Via Benzinga
Could Amgen's Heart Disease Candidate Generate Billions in Sales?
Amgen recently shared positive clinical trial results for a heart disease drug candidate. 
Via The Motley Fool
How An Eli Lilly Decision Could Light Up The Red-Hot Obesity Landscape — Again
Eli Lilly is expected to make a key decision for a next-generation obesity drug. 
Via Investor's Business Daily
Why Mirati Therapeutics Stock Lost Half Its Value In Just Three Days
The company is still planning a Phase 3 study in non-small cell lung cancer. 
Via Investor's Business Daily
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
48 49 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.